Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Dermatology
•
Atopic Dermatitis
What criteria do you utilize in deciding between different jak inhibitors for atopic dermatitis?
Abrocitinib (cibinqo) vs upadacitinib (rinvoq)
Related Questions
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
How do you decide between IL-4/IL-13 blockade (dupixent) versus IL-13 blockade only (Adbry) as treatments for Atopic Dermatitis?
When would you pursue genetic testing for severe recalcitrant atopic dermatitis?
How do you manage atopic dermatitis in patients who have failed dupilumab?
How does omalizumab play a role in the armamentarium of atopic dermatitis?
How do you counsel families of pediatric patients on methotrexate about live vaccine schedules?
What is your approach to managing moderate to severe atopic dermatitis in pregnancy?
Do you utilize AIT for atopic dermatitis if there is no AR present?
What is the longest interval that you have been able to stretch a biologic before losing efficacy?
Have you seen CD30+ lymphoproliferative skin lesions with Upadacitinib treatment of atopic dermatitis?